PMID- 37527783
OWN - NLM
STAT- MEDLINE
DCOM- 20240115
LR  - 20240115
IS  - 2567-689X (Electronic)
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 124
IP  - 1
DP  - 2024 Jan
TI  - Characterization and Usefulness of Clot-Fibrinolysis Waveform Analysis in 
      Critical Care Patients with Enhanced or Suppressed Fibrinolysis.
PG  - 40-48
LID - 10.1055/a-2145-7139 [doi]
AB  - INTRODUCTION:  Recently, clot-fibrinolysis waveform analysis (CFWA), which is a 
      coagulation and fibrinolysis global assay based on assessing the activated 
      partial thromboplastin time with tissue-type plasminogen activator, was 
      developed. This study aimed to investigate the characteristics of CFWA using 
      plasma samples from patients in the critical care unit. MATERIALS AND METHODS: 
       The fibrinolysis times using CFWA were measured in 298 plasma samples. These 
      samples were divided into three groups based on the reference interval (RI) of 
      fibrinolysis time using CFWA: shortened group, less than RI; within group, within 
      RI; prolonged group, more than RI. The coagulation and fibrinolysis markers, 
      including D-dimer, plasmin-alpha(2) plasmin inhibitor complex (PIC), fibrin monomer 
      complex (FMC), plasmin-alpha(2) plasmin inhibitor (alpha(2)-PI), plasminogen (Plg), and 
      fibrinogen (Fbg) were analyzed and compared among the three groups. RESULTS:  The 
      FMC level decreased in the order of shortened, within, and prolonged groups, and 
      the decrease was statistically significant among all three group pairs. The 
      opposite tendency was observed for Fbg and fibrinolysis-related markers of 
      alpha(2)-PI and Plg, and significant differences were recognized in all pair 
      comparisons except for between within and prolonged groups in Plg. The mean 
      values of the fibrinolysis markers D-dimer and PIC in all three groups were 
      higher than the cut-off values, and the PIC value differed significantly between 
      the within and prolonged groups. CONCLUSION:  The fibrinolysis reaction was 
      detected in all three groups, but the status differed. CFWA has the potential to 
      reflect the fibrinolysis status in one global assay.
CI  - The Author(s). This is an open access article published by Thieme under the terms 
      of the Creative Commons Attribution-NonDerivative-NonCommercial License, 
      permitting copying and reproduction so long as the original work is given 
      appropriate credit. Contents may not be used for commercial purposes, or adapted, 
      remixed, transformed or built upon. 
      (https://creativecommons.org/licenses/by-nc-nd/4.0/).
FAU - Tsuchida, Takumi
AU  - Tsuchida T
AUID- ORCID: 0000-0001-8868-0255
AD  - Division of Acute and Critical Care Medicine, Department of Anesthesiology and 
      Critical Care Medicine, Hokkaido University Faculty of Medicine, Sapporo, Japan.
FAU - Hayakawa, Mineji
AU  - Hayakawa M
AUID- ORCID: 0000-0001-8341-7626
AD  - Division of Acute and Critical Care Medicine, Department of Anesthesiology and 
      Critical Care Medicine, Hokkaido University Faculty of Medicine, Sapporo, Japan.
FAU - Kumano, Osamu
AU  - Kumano O
AUID- ORCID: 0000-0001-6650-0567
AD  - Sysmex Corporation, Kobe, Japan.
AD  - Health and Medical Research Institute, National Institute of Advanced Industrial 
      Science and Technology (AIST), Takamatsu, Japan.
LA  - eng
PT  - Journal Article
DEP - 20230801
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (alpha-2-Antiplasmin)
RN  - EC 3.4.21.7 (Fibrinolysin)
RN  - 0 (Antifibrinolytic Agents)
RN  - 9001-91-6 (Plasminogen)
RN  - 9001-32-5 (Fibrinogen)
SB  - IM
MH  - Humans
MH  - *Fibrinolysis
MH  - alpha-2-Antiplasmin
MH  - Fibrinolysin
MH  - Fibrin Clot Lysis Time
MH  - *Antifibrinolytic Agents
MH  - Plasminogen
MH  - Fibrinogen/pharmacology
MH  - Critical Care
PMC - PMC10783976
COIS- T.T. and M.H. declare that they have no competing interests. O.K. was an employee 
      of the Sysmex Corporation at the time the work was carried out.
EDAT- 2023/08/02 01:07
MHDA- 2024/01/15 12:42
PMCR- 2023/09/01
CRDT- 2023/08/01 19:12
PHST- 2024/01/15 12:42 [medline]
PHST- 2023/08/02 01:07 [pubmed]
PHST- 2023/08/01 19:12 [entrez]
PHST- 2023/09/01 00:00 [pmc-release]
AID - TH-23-02-0077 [pii]
AID - 10.1055/a-2145-7139 [doi]
PST - ppublish
SO  - Thromb Haemost. 2024 Jan;124(1):40-48. doi: 10.1055/a-2145-7139. Epub 2023 Aug 1.